WE hypothesized that foetal administration of 548, a 
Introduction
The arachidonic acid metabolite thromboxane (TX) causes peripheral vasoconstriction in the foetus and decreased utero-placental blood flow. These effects are balanced by the vasodilatory actions of prostacyclin (PGI). The normal term human placenta produces approximately equal amounts of TX and PGI. In contrast, in preeclampsia the placental production of TX is increased three-fold while PGI production is less than half of normal. This eicosanoid imbalance is central to current concepts of the pathophysiology of preeclampsia. This imbalance favours the vasoconstrictive effects of TX both peripherally and in the umbilical-placental circulation, 2 and has been postulated to account for the clinical manifestations of the disease. Potential therapy for this disorder should therefore be directed at correcting the TX/PGI imbalance. Potential methods to accomplish this include: increasing PGI production, inhibition of TX synthesis or blockade of the biological actions of TX. PGI administration has been evaluated in the maternal and foetal compartments without foetal benefit. In preeclamptic women, the clinical condition improves, although foetal distress and foetal demise after maternal PGI administration have been reported. Additionally, in vivo laboratory experiments have demonstrated significant reductions in umbilicalplacental blood flow occur when PGI is administered to the vasoconstricted ovine foetus. 4 ,s TX synthesis in the placenta in vitro can be reduced by the administration of low-dose aspirin 6'7 and clinical (C) (Fig. 4) was eectively blocked (Fig. 3) . The expected increase in placental vascular resistance with TX administration did not occur (Fig. 4) (Table 3 ).
Discussion
The finding of an imbalance in TX/PGI production by the human placenta in preeclampsia has stimulated discussion regarding potential therapy for this disease. Previous human research had focused on correcting the deficiency in PGI by increasing PGI. 3 Subsequent investigators have evaluated inhibition of thromboxane production both in vivo 8'9 and in vitro. 6"7 The foetus may be adversely affected by the increase in thromboxane production found in pregnancies complicated by preeclampsia. Since 
